Free Trial
→ This simple indicator removes the “technical” out of technical trading (From ProsperityPub) (Ad)

Zealand Pharma A/S Q4 2024 Earnings Report

Zealand Pharma A/S logo
$108.30 0.00 (0.00%)
As of 02/21/2025
Earnings HistoryForecast

Zealand Pharma A/S EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$1.30 million
Expected Revenue
$28.11 million
Beat/Miss
Missed by -$26.81 million
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Q4 2024
Date
2/20/2025
Time
Before Market Opens

Conference Call Resources

Zealand Pharma A/S Earnings Headlines

Zealand Pharma A/S (ZLDPF) Q4 2024 Earnings Call Transcript
February 20 at 4:06 PM | seekingalpha.com
Zealand Pharma convenes its Annual General Meeting 2025
February 20 at 12:23 PM | finance.yahoo.com
9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
February 23, 2025 | Wealthpin Pro (Ad)
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
February 13, 2025 | globenewswire.com
Zealand Pharma initiated with an Equal Weight at Morgan Stanley
February 12, 2025 | markets.businessinsider.com
Zealand Pharma downgraded to Hold from Buy at SEB Equities
January 29, 2025 | markets.businessinsider.com
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

View Zealand Pharma A/S Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles